4′‐modified nucleoside analogs: Potent inhibitors active against entecavir‐resistant hepatitis B virus

Abstract

These data provide insights on the structural and functional associations of HBV- and HIV-1-RTs and show that CAdA may offer new therapeutic options for HBV patients.